Ironwood Pharmaceuticals Earnings Estimate
| IRWD Stock | USD 3.36 0.43 11.35% |
Ironwood Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Ironwood Pharmaceuticals' earnings estimates, investors can diagnose different trends across Ironwood Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At present, Ironwood Pharmaceuticals' Operating Profit Margin is projected to slightly grow based on the last few years of reporting. The current year's Net Profit Margin is expected to grow to 0.41, whereas Gross Profit is forecasted to decline to about 221.3 M. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.
Ironwood Pharmaceuticals Earnings per Share Projection vs Actual
About Ironwood Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Ironwood Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Ironwood Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Ironwood Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.5 B | -1.5 B | |
| Retained Earnings Total Equity | -626.7 M | -658.1 M | |
| Earnings Yield | 0.21 | 0.22 | |
| Price Earnings Ratio | 4.71 | 4.48 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.